Diabetes insipidus

Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market

Retrieved on: 
Lunedì, Aprile 15, 2024
Hospitals, Pharmaceutical, Health, Cardiology, FDA, Administration, Boxed warning, Respiratory arrest, Injury, Bleeding, Risk, Factor VIII, Food, Hemarthrosis, Warning, Hyponatremia, Death, Polydipsia, Seizure, Contraindication, Patient, Diabetes insipidus, Central diabetes insipidus, Haemophilia, Coma, Pharmaceutical industry

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.

Key Points: 
  • Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin Acetate) approved by the U.S. Food and Drug Administration.
  • Desmopressin Acetate for Injection is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von Willebrand’s disease (Type I).
  • View the full release here: https://www.businesswire.com/news/home/20240415847399/en/
    Avenacy’s Desmopressin Acetate for Injection is available in two presentations: 4 mcg per 1 mL single-dose vials, and 40 mcg per 10 mL multiple-dose vials.
  • Avenacy will begin shipping Desmopressin Acetate for Injection to wholesale partners this week.

Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

Retrieved on: 
Mercoledì, Giugno 14, 2023
General Health, Pharmaceutical, Health, Cardiology, Blood pressure, Hypersensitivity, Bradycardia, Tachycardia, Indometacin, Use, Fresenius (company), Allergy, Safety, Hyponatremia, Multimedia, USP, Cardiac output, Endo International, Ischemia, Hospital, Patient, Catecholamine, FDA, Diabetes insipidus, Hypotension, Skin, Beta blocker, SIADH, Pharmaceutical industry, Birth control, Vaccine, Dentistry, Vasopressin

Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.

Key Points: 
  • Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.
  • Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.
  • Fresenius Kabi produces Vasopressin Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems.
  • To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “ More in America .”
    Please see Important Safety Information below.

Worldwide Kidney Function Tests Industry to 2028 - Increase in Awareness of Diagnostic Techniques for Kidney Function Drives Growth

Retrieved on: 
Giovedì, Febbraio 23, 2023
Metastasis, Diabetes insipidus, Internet of things, Immunoglobulin A, DSS, Urine, Deep learning, Abbott Laboratories, Diabetes, Acute kidney injury, Swelling, Chronic kidney disease, Kidney failure, Danaher Corporation, Internet, Kidney disease, Patient, CKD, Conditional sentence, Fresenius Medical Care, Baxter International, Labcorp, Kidney, CDC, ANN, Hospital, Sysmex Corporation, Cystic kidney disease, Death, Growth, Korea Disease Control and Prevention Agency, Laboratory, Idexx Laboratories, Blood, Goodpasture syndrome, System, Urination, Prevalence, AKI, Diagnosis, Dialysis, IgA nephropathy, Amyloidosis, Risk, Hypertension, Siemens Healthineers, Randox, Regeneration, Pharmaceutical industry, Phosphorus, Dietary supplement, Medical device

The growth of the global market for kidney function tests is anticipated to be supported by an increase in awareness of diagnostic techniques for kidney function.

Key Points: 
  • The growth of the global market for kidney function tests is anticipated to be supported by an increase in awareness of diagnostic techniques for kidney function.
  • This, in turn, is expected to drive the growth of the global kidney function tests market.
  • This, in turn, is expected to positively influence the growth of the global kidney function tests market.
  • In this report, global kidney function tests market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Agosto 18, 2022
Health, Pharmaceutical, Nutrition, Hypothyroidism, Addison's disease, Fatty liver disease, Non-alcoholic fatty liver disease, Vitamin, Liver disease, Directory, Technology, Metabolism, Diabetes insipidus, SEC, Cushing's syndrome, Chapter Four, Chapter Five, Chapter Three, Lysosomal storage disease, Diabetes, Review, NASH, Contract, Syndrome of inappropriate antidiuretic hormone secretion, Syndrome, Biotechnology, Metabolic disorder, Chapter Six, Thyroid disease, SIADH, Chapter One, Chapter Two, Gallstone, Rickets, Hyperlink, Collection, Acromegaly, Orientation, Cirrhosis, A-Z, Pharmaceutical industry, Risk management, Pheochromocytoma, Hypercalcaemia, Hypogonadism, Hypocalcemia, Hyperaldosteronism, Phenylketonuria, Hypopituitarism, Hyperthyroidism

Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.

Key Points: 
  • Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.
  • The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
  • In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2015.
  • Global Metabolic Partnering 2015 to 2022 includes:
    In Global Metabolic Partnering 2015 to 2022, available deals and contracts are listed by:

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Retrieved on: 
Mercoledì, Maggio 12, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Kidney diseases, Rare diseases, Antidiuretics, Thirst, Nephrogenic diabetes insipidus, Diabetes insipidus, NDI, Vasopressin, Kidney disease, NDI-5033, NephroDI Therapeutics, Inc., Xontogeny, LLC, NDI-5033, NEPHRODI THERAPEUTICS, INC., XONTOGENY, LLC

NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin.

Key Points: 
  • NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin.
  • If hydration is not maintained, it can cause mental retardation and even chronic kidney disease by middle school age.
  • The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus (NDI) in children, a pediatric orphan indication.
  • NephroDI Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005297/en/\n'

Advisory - Three lots of antidiuretic DDAVP Spray recalled because of potential overdose risk

Retrieved on: 
Giovedì, Luglio 16, 2020
Medical specialties, Organ systems, Medicine, RTT, Rare diseases, Endocrine diseases, Nephrology, Thirst, Desmopressin, Diabetes insipidus, Antidiuretic, Central diabetes insipidus

Product: DDAVP Spray (desmopressin acetate nasal solution, 10 micrograms/spray)

Key Points: 
  • Product: DDAVP Spray (desmopressin acetate nasal solution, 10 micrograms/spray)
    Issue:Three lots are being recalled because the product may contain a higher than labelled dose of the active ingredient (desmopressin) and could pose an overdose risk.
  • What to do: Check the lot number on your product or contact your pharmacist to determine whether your product is being recalled.
  • Ferring Inc. is recalling three lots of DDAVP Spray (desmopressin acetate nasal solution, 10 micrograms/spray) because the product may contain a higher than labelled dose of the active ingredient (desmopressin) and could pose an overdose risk.
  • DDAVP Spray is a prescription antidiuretic drug used to treat an uncommon brain disorder called central diabetes insipidus (genetic or acquired) caused by a deficiency of antidiuretic hormone (ADH).